The Institute of Cancer Research, London, is one of the world’s most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years. We provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today, The Institute of Cancer Research (ICR) leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment.
Under the leadership of our Chief Executive, Professor Paul Workman FRS, the ICR is ranked as the UK’s leading academic research centre. Together with our partner The Royal Marsden, we are rated in the top four cancer centres globally.
The ICR is committed to attracting, developing and retaining the best minds in the world to join us in our mission – to make the discoveries that defeat cancer.
The Cancer Research UK Cancer Therapeutics Unit, part of the Division of Cancer Therapeutics, is a multidisciplinary 'bench to bedside' centre, comprising around 160 staff dedicated to the discovery and development of novel therapeutics for the treatment of cancer. The CR-UK Cancer Therapeutics Unit’s exciting goal is to discover high quality drug candidates for validated biological targets and to progress these candidates to clinical trial. All the scientific disciplines are in place to make this possible, including medicinal chemistry, biology, drug metabolism and clinical specialists.
A Post-Doctoral Training Fellow position in computational chemistry and molecular modelling is now available in our In Silico Medicinal Chemistry group. The successful candidate will be expected to learn and apply in silico medicinal chemistry techniques that impact across the CR-UK Cancer Therapeutics Unit portfolio of drug discovery projects. The candidate will provide close support to scientists in our Hit Discovery and Structural Design Team, and contribute to expand the capabilities of the In-Silico medicinal chemistry group.
Applicants must have a PhD, which may be in an area of molecular modelling, computational chemistry, or cheminformatics, with experience of application of computational techniques in drug discovery projects. Alternatively, applicants may have a PhD in medicinal chemistry or drug design with appropriate experience in the use of computational techniques.
KEY DUTIES & RESPONSIBILITIES
• Work collaboratively within multidisciplinary project teams to design compounds with improved potency, selectivity, functional activity and ADMET properties.
• Apply a full-range of computational techniques to address questions in drug discovery programs.
• Develop new computational techniques, and implement state-of-the-art procedures to expand capabilities of the in silico medicinal chemistry group at the ICR, and improve the impact of computer aided drug design on drug discovery.
• Effectively communicate with project teams and senior staff both in formal and informal meetings.
• Publish or present original work and/or literature reviews at conferences and/or in peer reviewed journals, while maintaining an up to date knowledge of literature and recent developments within the field of computational chemistry.
• Provide guidance to scientists from different disciplines to enable them to use computational tools appropriately and effectively.
• All staff must ensure that they familiarise themselves with and adhere to any ICR policies that are relevant to their work and that all personal and sensitive personal data is treated with the utmost confidentiality and in line with the General Data Protection Regulations.
Informal enquiries are welcome and can be made to Dr Mirco Meniconi (
[email protected]). Applications must be submitted online, via the e-recruitment system – please visit
https://www.icr.ac.uk/careers
